Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells

Yue Qin,Qi Cui,Guihua Sun,Jianfei Chao,Cheng Wang,Xianwei Chen,Peng Ye,Tao Zhou,Arjit Vijey Jeyachandran,Olivia Sun,Wei Liu,Shunyu Yao,Chance Palmer,Xuxiang Liu,Vaithilingaraja Arumugaswami,Wing C Chan,Xiuli Wang,Yanhong Shi

DOI: https://doi.org/10.1016/j.celrep.2024.114867

2024-11-26

Abstract:Cancer immunotherapy is gaining increasing attention. However, immune checkpoints are exploited by cancer cells to evade anti-tumor immunotherapy. Here, we knocked out NKG2A, an immune checkpoint expressed on natural killer (NK) cells, in human pluripotent stem cells (hPSCs) and differentiated these hPSCs into NK (PSC-NK) cells. We show that NKG2A knockout (KO) enhances the anti-tumor and anti-viral capabilities of PSC-NK cells. NKG2A KO endows PSC-NK cells with higher cytotoxicity against HLA-E-expressing glioblastoma (GBM) cells, leukemia cells, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected cells in vitro. The NKG2A KO PSC-NK cells also exerted potent anti-tumor activity in vivo, leading to substantially suppressed tumor progression and prolonged survival of tumor-bearing mice in a xenograft GBM mouse model. These findings underscore the potential of PSC-NK cells with immune checkpoint KO as a promising cell-based immunotherapy. The unlimited supply and ease of genetic engineering of hPSCs makes genetically engineered PSC-NK an attractive option for easily accessible "off-the-shelf" cancer immunotherapy.